Literature DB >> 33157162

Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.

Sen Yu1, Chunyu Zhang1, Ke-Ping Xie2.   

Abstract

Pancreatic cancer is a lethal disease with limited opportunity for resectable surgery as the first choice for cure due to its late diagnosis and early metastasis. The desmoplastic stroma and cellular genetic or epigenetic alterations of pancreatic cancer impose physical and biological barriers to effective therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Here, we review the current therapeutic options for pancreatic cancer, and underlying mechanisms and potential reversal of therapeutic resistance, a hallmark of this deadly disease.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Chemotherapy; Immunotherapy; Pancreatic cancer; Radiotherapy; Therapeutic resistance

Year:  2020        PMID: 33157162     DOI: 10.1016/j.bbcan.2020.188461

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  17 in total

1.  Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1).

Authors:  Dongcheng Luo; Sina Liao; Qian Li; Youzhi Lin; Junbao Wei; Yongqiang Li; Xiaoli Liao
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

2.  The Orexin-A/OX1R System Induces Cell Death in Pancreatic Cancer Cells Resistant to Gemcitabine and Nab-Paclitaxel Treatment.

Authors:  Thierry Voisin; Pascal Nicole; Valérie Gratio; Anaïs Chassac; Dounia Mansour; Vinciane Rebours; Anne Couvelard; Alain Couvineau
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor.

Authors:  Lara Diego-González; Andrea Fernández-Carrera; Ana Igea; Amparo Martínez-Pérez; M Elisabete C D Real Oliveira; Andreia C Gomes; Carmen Guerra; Mariano Barbacid; África González-Fernández; Rosana Simón-Vázquez
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

Review 4.  The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy.

Authors:  Yu-Hsuan Hung; Li-Tzong Chen; Wen-Chun Hung
Journal:  Biomedicines       Date:  2022-04-18

Review 5.  Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.

Authors:  Tomas Koltai; Stephan Joel Reshkin; Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Khalid Omer Alfarouk; Rosa Angela Cardone
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

6.  Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer.

Authors:  Shi-Lei Liu; Hai-Bin Liang; Zi-Yi Yang; Chen Cai; Zi-You Wu; Xiang-Song Wu; Ping Dong; Mao-Lan Li; Lei Zheng; Wei Gong
Journal:  Int J Med Sci       Date:  2022-01-04       Impact factor: 3.738

Review 7.  Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches.

Authors:  Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Tomas Koltai; Khalid O Alfarouk; Stephan J Reshkin; Rosa A Cardone
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

8.  Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth.

Authors:  Alessandra Rosati; Liberato Marzullo; Margot De Marco; Vanessa Gauttier; Sabrina Pengam; Caroline Mary; Bianca Ranieri; Anna Basile; Michela Festa; Antonia Falco; Francesca Reppucci; Anna Lisa Cammarota; Fausto Acernese; Vincenzo De Laurenzi; Gianluca Sala; Sergio Brongo; Masayuki Miyasaka; Shabnam Shalapour; Bernard Vanhove; Nicolas Poirier; Roberta Iaccarino; Michael Karin; Maria Caterina Turco
Journal:  Cell Death Discov       Date:  2022-03-03

Review 9.  Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma.

Authors:  Marcus T T Roalsø; Øyvind H Hald; Marina Alexeeva; Kjetil Søreide
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

10.  Factors Affecting the Readmission of Patients with Pancreatic Cancer after Surgery.

Authors:  Xiaojing Gu; Wei Zhou; Juan Han
Journal:  Appl Bionics Biomech       Date:  2022-04-29       Impact factor: 1.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.